Journal
BLOOD
Volume 118, Issue 16, Pages 4359-4362Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-03-342089
Keywords
-
Categories
Funding
- National Cancer Institute, National Institutes of Health
- Department of Health and Human Services [CA23318, CA66636, CA21115, CA13650, CA93842]
- National Institutes of Health [CA90628]
- Celgene
Ask authors/readers for more resources
Detection of specific chromosomal abnormalities by FISH and metaphase cytogenetics allows risk stratification in multiple myeloma; however, gene expression profiling (GEP) based signatures may enable more specific risk categorization. We examined the utility of 2 GEP-based risk stratification systems among patients undergoing initial therapy with lenalidomide in the context of a phase 3 trial. Among 45 patients studied at baseline, 7 (16%) and 10 (22%), respectively, were high-risk using the GEP70 and GEP15 signatures. The median overall survival for the GEP70 high-risk group was 19 months versus not reached for the rest (hazard ratio = 14.1). Although the medians were not reached, the GEP15 also predicted a poor outcome among the high-risk patients. The C-statistic for the GEP70, GEP15, and FISH based risk stratification systems was 0.74, 0.7, and 0.7, respectively. Here we demonstrate the prognostic value for GEP risk stratification in a group of patients primarily treated with novel agents. This trial was registered at www.clinicaltrials.gov as #NCT00098475. (Blood. 2011; 118(16):4359-4362)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available